Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Neuropathic Pain
Interventions
DRUG

onabotulinum toxin A

Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.

Trial Locations (1)

40536

Orofacial Pain Center, Lexington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Isabel Moreno Hay

OTHER